Phoenix Laser Systems
This article was originally published in The Gray Sheet
Executive Summary
Bernard Szeto, a member of an investor group that opposes the firm's proposed reorganization ("The Gray Sheet" April 19, p. 33), files suit in Delaware Court of Chancery "seeking injunctive relief, recision and damages based on allegations that Phoenix' management had, in violation of Delaware law, transferred all of Phoenix' assets to two new companies which would not be controlled by Phoenix," according to an April 19 Phoenix release. Phoenix maintains that "the lawsuit is without merit and will be defended vigorously." According to an April 14 Securities and Exchange Commission filing made by the investor group, Szeto filed a separate suit on March 29 in the Delaware court seeking to compel Phoenix to schedule an annual shareholders meeting. At the meeting, the investors would nominate "a slate of new directors" independent of Phoenix Chairman and CEO Steven Schiffer and would ask for a recision of transactions "related to the transfer of Phoenix assets to companies controlled by Mr. Schiffer." On April 6, Phoenix filed a suit against the investors in California Superior Court charging them with "misappropriation of funds" and acting in accordance with a plan to take over control of the firm.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.